Literature DB >> 3942987

Recurrence potential of thin primary melanomas.

P L Naruns, J A Nizze, A J Cochran, M B Lee, D L Morton.   

Abstract

Between April 1971 and January 1985, the University of California at Los Angeles (UCLA) Division of Surgical Oncology has seen 649 patients diagnosed with thin primary melanomas, as defined by a Clark level less than IV and Breslow depth less than 0.76 mm. Thirty-six patients, whose primary diagnosis was confirmed by UCLA pathologists, presented with or subsequently developed melanoma metastases. Twenty-four (67%) had Clark level II lesions, whereas the remaining 12 (33%) had Clark level III lesions. Metastases were noted more frequently in men than in women, with a man-to-woman ratio of 3 to 2. The site of the primary lesion in this group was most frequently on the trunk (16 of 36 cases, 44%), followed by the head and neck (9 of 36 cases, 25%) and arm and shoulder (7 of 36 cases, 19%). Metastasizing thin lesions were least likely to occur on the leg and hip (4 of 36 cases, 11%). Twenty of these lesions were recently reexamined, and 17 of 20 cases (85%) demonstrated evidence of regression. Twenty-eight patients (78%) had their first metastases to regional lymph nodes. Fifteen remained alive with no evidence of disease at a median follow-up of 99 months. Twenty patients died from systemic metastases, and one patient was alive with brain metastasis at the time of this article. Although infrequent, metastases from thin melanomas do occur, suggesting the need for careful long-term follow-up and immediate investigation of adenopathy even in low-risk patients.

Entities:  

Mesh:

Year:  1986        PMID: 3942987     DOI: 10.1002/1097-0142(19860201)57:3<545::aid-cncr2820570323>3.0.co;2-k

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

1.  The significance of inflammation and regression in melanoma.

Authors:  M G Cook
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

Review 2.  Surgery and sentinel lymph node biopsy.

Authors:  Mark B Faries; Donald L Morton
Journal:  Semin Oncol       Date:  2007-12       Impact factor: 4.929

Review 3.  Regressing thin cutaneous malignant melanomas (< or = 1.0 mm) are associated with angiogenesis.

Authors:  R L Barnhill; M A Levy
Journal:  Am J Pathol       Date:  1993-07       Impact factor: 4.307

4.  Regression in primary cutaneous melanoma: etiopathogenesis and clinical significance.

Authors:  Phyu P Aung; Priyadharsini Nagarajan; Victor G Prieto
Journal:  Lab Invest       Date:  2017-02-27       Impact factor: 5.662

5.  Cutaneous melanomas exhibiting unusual biologic behavior.

Authors:  H M Shaw; J K Rivers; S W McCarthy; W H McCarthy
Journal:  World J Surg       Date:  1992 Mar-Apr       Impact factor: 3.352

6.  Predictors of occult nodal metastasis in patients with thin melanoma.

Authors:  Mark B Faries; Leslie A Wanek; David Elashoff; Byron E Wright; Donald L Morton
Journal:  Arch Surg       Date:  2010-02

7.  Malignant melanoma simulants arising in congenital melanocytic nevi do not show experimental evidence for a malignant phenotype.

Authors:  M L Mancianti; W H Clark; F A Hayes; M Herlyn
Journal:  Am J Pathol       Date:  1990-04       Impact factor: 4.307

8.  Lethal "thin" malignant melanoma. Identifying patients at risk.

Authors:  C L Slingluff; R T Vollmer; D S Reintgen; H F Seigler
Journal:  Ann Surg       Date:  1988-08       Impact factor: 12.969

9.  Morphometric, DNA and PCNA in thin malignant melanomas.

Authors:  V Björnhagen; E Månsson-Brahme; J Lindholm; A Mattsson; G Auer
Journal:  Med Oncol Tumor Pharmacother       Date:  1993

10.  Extent of vascularization as a prognostic indicator in thin (< 0.76 mm) malignant melanomas.

Authors:  C H Graham; J Rivers; R S Kerbel; K S Stankiewicz; W L White
Journal:  Am J Pathol       Date:  1994-09       Impact factor: 4.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.